Analysts Set Expectations for SCPH FY2029 Earnings

scPharmaceuticals Inc. (NASDAQ:SCPH) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for scPharmaceuticals in a report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao expects that the company will earn $0.70 per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share.

Separately, Craig Hallum decreased their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

scPharmaceuticals Trading Down 3.3 %

NASDAQ SCPH opened at $3.18 on Wednesday. scPharmaceuticals has a 52 week low of $3.08 and a 52 week high of $6.20. The firm has a 50 day moving average of $3.39 and a two-hundred day moving average of $3.96. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $159.13 million, a PE ratio of -1.67 and a beta of 0.11.

Institutional Investors Weigh In On scPharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans increased its stake in scPharmaceuticals by 1.4% in the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after purchasing an additional 14,866 shares during the last quarter. King Luther Capital Management Corp boosted its holdings in shares of scPharmaceuticals by 0.9% in the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after buying an additional 20,650 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of scPharmaceuticals in the 3rd quarter valued at $57,000. BNP Paribas Financial Markets grew its position in shares of scPharmaceuticals by 116.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after buying an additional 3,101 shares during the last quarter. Finally, Rubric Capital Management LP raised its stake in scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after acquiring an additional 1,250,000 shares in the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.